Skip to main content

Research Repository

Advanced Search

Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials

Robson, Joanna; Doll, Helen; Suppiah, Ravi; Flossmann, Oliver; Harper, Lorraine; H�glund, Peter; Jayne, David; Mahr, Alfred; Westman, Kerstin; Luqmani, Raashid

Authors

Jo Robson Jo.Robson@uwe.ac.uk
Consultant Associate Professor in Rheumatology

Helen Doll

Ravi Suppiah

Oliver Flossmann

Lorraine Harper

Peter H�glund

David Jayne

Alfred Mahr

Kerstin Westman

Raashid Luqmani



Abstract

Objectives To describe short-term (up to 12 months) and long-term (up to 7 years) damage in patients with newly diagnosed antineutrophil-cytoplasm antibody-associated vasculitis (AAV).

Methods Data were combined from six European Vasculitis Study group trials (n=735). Long-term follow-up (LTFU) data available for patients from four trials (n=535). Damage accrued was quantified by the Vasculitis Damage Index (VDI). Sixteen damage items were defined a priori as being potentially treatment-related.

Results VDI data were available for 629 of 735 patients (85.6%) at baseline, at which time 217/629 (34.5%) had ≥1 item of damage and 32 (5.1%) ≥5 items, reflecting disease manifestations prior to diagnosis and trial enrolment. LTFU data were available for 467/535 (87.3%) at a mean of 7.3 years postdiagnosis. 302/535 patients (56.4%) had VDI data at LTFU, with 104/302 (34.4%) having ≥5 items and only 24 (7.9%) no items of damage. At 6 months and LTFU, the most frequent items were proteinuria, impaired glomerular filtration rate, hypertension, nasal crusting, hearing loss and peripheral neuropathy. The frequency of damage, including potentially treatment-related damage, rose over time (p < 0.01). At LTFU, the most commonly reported items of treatment-related damage were hypertension (41.5%; 95% CI 35.6 to 47.4%), osteoporosis (14.1%; 9.9 to 18.2%), malignancy (12.6%; 8.6 to 16.6%), and diabetes (10.4%; 6.7 to 14.0%).

Conclusions In AAV, renal, otolaryngological and treatment-related (cardiovascular, disease, diabetes, osteoporosis and malignancy) damage increases over time, with around one-third of patients having ≥5 items of damage at a mean of 7 years postdiagnosis.

Journal Article Type Article
Acceptance Date Oct 29, 2013
Online Publication Date Nov 15, 2013
Publication Date Jan 1, 2015
Deposit Date Jul 2, 2019
Journal Annals of the Rheumatic Diseases
Print ISSN 0003-4967
Electronic ISSN 1468-2060
Publisher BMJ Publishing Group
Peer Reviewed Peer Reviewed
Volume 74
Issue 1
Pages 177-184
DOI https://doi.org/10.1136/annrheumdis-2013-203927
Public URL https://uwe-repository.worktribe.com/output/1467261
Publisher URL https://doi.org/10.1136/annrheumdis-2013-203927